Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ...

The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

Baltimore's beloved live music tradition, Jazzy Summer Nights is well into its 25th and final season. This farewell season, ...

Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.

Lenacapavir, the injectable drug developed by a US-based company, Gilead Sciences, was trialled (tested) in Uganda and South ...

HIV treatment stops the HIV replication that causes immune damage. But there are places in the body where the virus "hides" ...

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

This article discusses the DOJ’s growing crackdown on healthcare fraud, focusing on illegal speaker programs like Gilead’s $202 million settlement. It stresses the importance of strong compliance, ...